Research analysts at HC Wainwright cut their Q1 2025 earnings estimates for Axsome Therapeutics in a research report issued ...

We recently published a list of the 10 Best Performing Pharma Stocks So Far in 2025. In this article, we are going to take a ...

Axsome Therapeutics (NASDAQ:AXSM – Get Free Report) had its target price increased by equities research analysts at HC ...

Q4 2024 Earnings Call Transcript February 18, 2025 Axsome Therapeutics, Inc. misses on earnings expectations. Reported EPS is ...

We recently published a list of the 10 Best Performing Healthcare Stocks So Far in 2025. In this article, we are going to ...

In this article, we are going to take a look at where Axsome Therapeutics, Inc. (NASDAQ:AXSM) stands against other best performing healthcare stocks so far in 2025. Despite the ongoing craze ...

Axsome Therapeutics, Inc. (NASDAQ:AXSM) is a commercial-stage biopharmaceutical company that develops and delivers therapies for central nervous system (CNS) conditions with limited treatment options.

Axsome Therapeutics Inc (NASDAQ:AXSM) reported strong financial performance with total net product revenue of $386 million for 2024, reflecting high double-digit year-over-year growth. The company ...

Highlights,Multiple financial firms have provided positive ratings for Axsome Therapeutics, reflecting confidence in the ...

Axsome Therapeutics (NASDAQ:AXSM) stock rallied 15% in morning trading on news it has settled patent litigation with Teva (NYSE:TEVA) over its antidepressant drug Auvelity. Axsome (NASDAQ ...